Prostate Cancer Clinical Trials

Showing 721-740 of 2,150 trials

An Investigational Scan (18F-Fluciclovine PET-CT) for the Measurement of Therapeutic Response in Patients With Metastatic Prostate Cancer

NCT04134208

This phase IV trial studies how well an investigational scan (18F-fluciclovine PET-CT) works for the measurement of therapeutic response in patients with prostate cancer that has spread to other places in the body (metastatic). 18F-fluciclovine is a radioactive substance that is used in this study with PET-CT imaging scans that may help doctors learn about response to standard therapy in patients with prostate cancer.

Metastatic Prostate CarcinomaStage IVB Prostate Cancer AJCC v8

M.D. Anderson Cancer Center2 participantsStarted Sep 2019

Houston, Texas, United States

COMPLETEDPhase 1/2

Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours

NCT03518606

This is a phase I/II national, multicentre, multiple cohort, prospective open-label, non-randomised and non-comparative study, to evaluate the safety and activity of metronomic oral vinorelbine associated with durvalumab + tremelimumab combination immunotherapy for the treatment of advanced solid tumours.

Advanced Solid TumoursBreast CancerHead and Neck Cancer+2 more

UNICANCER126 participantsStarted Jun 2018

Angers, France • Caen, France • Dijon, France +6 more locations

RECRUITINGPhase 1

Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies

NCT05488548

A Phase 1, first-in-human study of EP31670, a dual BET and CBP/p300 inhibitor in patients with targeted advanced solid tumors and Hematological Malignancies

Castrate Resistant Prostate CancerNUT CarcinomaChronic Myelomonocytic Leukemia+1 more

Epigenetix, Inc.75 participantsStarted Dec 2022

Phoenix, Arizona, United States • Jacksonville, Florida, United States • Boston, Massachusetts, United States +3 more locations

An Investigational Scan (18F-Fluciclovine PET-CT) for the Measurement of Therapeutic Response in Patients With Metastatic Prostate Cancer

Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours

Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies

Related Searches

Community Interventions in Non-medical Settings to Increase Informed Decision Making for Prostate Cancer Screening

A Non-Interventional Study to Evaluate Time to Event and Healthcare Resource Utilisation for Prostate Cancer Participants Throughout the Disease Trajectories Until Progression or Death

Physical Function During ARSI Treatment

Implementation of a New Algorithm for HRR Gene Mutation Testing in Patients With mPC Through Liquid Biopsy Integration

Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma

Preoperative PSMA PET/CT As Triage for EPLND in Patients Scheduled for RALP (PrePSMA)

Intensive Diet and Exercise or Standard of Care in Improving Physical Function and Quality of Life in Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy

A Cluster Package Intervention to Promote an Evidence-based Use of PSA-tests in General Practice

Radiation Therapy in Treating Patients Receiving Hormone Therapy for Prostate Cancer (GETUG-AFU 18)

A Multicenter Study Evaluating the Diagnostic Value of 68Ga-MY6349 PET/CT for Prostate Cancer

PSMA-PET/CT Registry

A Phase I/IIa Study of UV1 Vaccine in Patients With Prostate Cancer

Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer

Comprehensive Outcomes for After Cancer Health

Evaluating Respiratory Effects of Driving Pressure Guided Mechanical Ventilation Using Electrical Impedance Tomography in Patients Undergoing Robot-Assisted Laparoscopic Radical Prostatectomy

Assessing DNA Changes in High Risk Prostate Cancer to Determine Prognosis

Head-to-head Comparison of 68Ga-PSMA-11 and 18F-PSMA-1007